Kineta reopens VISTA-101 trial; 30 of 39 patients enrolled; KVA12123 safe

TuHURA Biosciences, Inc./NV

Kineta reopened enrollment in VISTA-101 Phase 1/2 trial for KVA12123; expects full enrollment by end of 2024.
30 of projected 39 patients enrolled; cleared 5th of 6 monotherapy dose levels and 2 of 4 combination cohorts.
Initial results showed partial response and stable disease in combo cohorts; durable stable disease in monotherapy.
KVA12123 demonstrated no dose-limiting toxicities and no CRS-associated cytokines at any dose level.
TuHURA has exclusive right to negotiate acquisition until Oct 1, 2024 (extendable) after $5M nonrefundable payment.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.